Rastislav Bahleda

6.4k citations
75 papers · 5.0k · 3 hit papers · h-index 24

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Colorectal Cancer Treatments and Studies
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Immunotherapy and Biomarkers 9
    • Colorectal Cancer Treatments and Studies 7
    • CAR-T cell therapy research 6
    • HER2/EGFR in Cancer Research 5
    • Sarcoma Diagnosis and Treatment 9
    • Lung Cancer Treatments and Mutations 6

Rastislav Bahleda

67 papers receiving 4.9k citations

Rastislav Bahleda's Hit Papers

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study 2021 · 209 citations
2090+3+6Years since publication50010001.5k

Peers

Rastislav Bahleda
Comparison fields: 5 of 113
  • Oncology 2.5k
  • Cancer Research 602
  • Pulmonary and Respiratory Medicine 1.1k
  • Immunology 586
  • Otorhinolaryngology 104
Replace Albiruni R. Abdul Razak with:
Albiruni R. Abdul Razak Canada
Jimmy J. Hwang United States
Anas Gazzah France
Dimitrios I. Bafaloukos Greece
Andrea Varga France
Zachary Rockow Chalmers United States
Drew Warren Rasco United States
Coraline Dubot France
Valentina Boni Spain
Karolina Sikorska Netherlands
Rastislav Bahleda relative to Albiruni R. Abdul Razak Canada Albiruni R. Abdul Razak's profile →
Citations per field
00.5×1.5×1.8×
Albiruni R. Abdul Razak · 1×
Citations per year

Countries citing papers authored by Rastislav Bahleda

Since Specialization
Citations

This map shows the geographic impact of Rastislav Bahleda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rastislav Bahleda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rastislav Bahleda more than expected).

Fields of papers citing papers by Rastislav Bahleda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rastislav Bahleda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rastislav Bahleda. The network helps show where Rastislav Bahleda may publish in the future.

Co-authors

The 25 scholars most cited alongside Rastislav Bahleda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rastislav Bahleda Line = papers co-authored together Rastislav Bahleda links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Hit paper breakdown →
20161785
2
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Hit paper breakdown →
2017597
3 2015338
4 2019211
5
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study
Hit paper breakdown →
2021209
6 2013174
7 2017170
8 2019163
9 2016130
10 2020125
11 2018118
12 2019102
13 201993
14 202168
15 202358
16 201352
17 201750
18 202446
19 201344
20 201242

About Rastislav Bahleda

Rastislav Bahleda is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Molecular Biology, having authored 75 papers that have together received 5.0k indexed citations. Recurring topics across this work include Fibroblast Growth Factor Research (12 papers), Sarcoma Diagnosis and Treatment (9 papers), Cancer Immunotherapy and Biomarkers (9 papers), Colorectal Cancer Treatments and Studies (7 papers), Cancer Genomics and Diagnostics (6 papers), CAR-T cell therapy research (6 papers), Lung Cancer Treatments and Mutations (6 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Oncology (2.5k citations), Cancer Research (602 citations), Pulmonary and Respiratory Medicine (1.1k citations), Immunology (586 citations) and Otorhinolaryngology (104 citations). Rastislav Bahleda has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Jean‐Charles Soria, Antoîne Italiano, Christophe Massard, Antoine Hollebecque, Anas Gazzah, Ben Tran, Hendrik‐Tobias Arkenau, Lipika Goyal, Funda Meric‐Bernstam and Emiliano Calvo. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Clinical Cancer Research, Investigational New Drugs and Cancer Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact